for CRPC. We thus queried gene-expression data sets from human benign, primary prostate cancer and metastatic prostate cancer samples, and searched for NRs with altered expression in mCRPC, as compared to their expression in benign and primary tumor tissue. In both data sets, the expression of RORA and RORB was significantly lower (all P < 0.05) in metastatic tumors than in benign prostate tissue or localized tumors ( Supplementary Fig. 1a) ; by contrast, the expression of RORC was significantly higher (P = 7.0 × 10 −4 and P = 6.1 × 10 −6 , respectively, for the two data sets) in metastatic tumors (Fig. 1a) . In addition, RORC was amplified in 6% of mCRPC tumors in a recent study 18 ( Supplementary Fig. 1a ). Immunohistochemical analysis of benign prostate and prostate tumors revealed that nuclear ROR-γ is overexpressed in more than 50% of the tumors, and that high levels of ROR-γ protein are significantly associated with tumor metastasis (P = 0.0012; Fig. 1b and Supplementary Fig. 1b) . ROR-γ protein was detected readily by immunoblotting in AR-positive cancer cell lines derived from CRPC tumors (for example, LNCaP, C4-2B, 22Rv1, VCaP, PC346C and LAPC4), but not in the nonmalignant human prostate epithelial cells (RWPE1 and PNT-2) (Fig. 1c) .
Next, we examined the function of ROR-γ in prostate cancer. Knockdown of ROR-γ by different RORC siRNAs markedly inhibited the growth of LNCaP cells and its CRPC-derivative C4-2B cells ( Fig. 1d and Supplementary Fig. 1c ). Such strong growth inhibition was also observed in other androgen-sensitive and CRPC models, such as VCaP and 22Rv1, but not in AR-negative PC-3 cells. ROR-γ knockdown also resulted in the induction of apoptosis, as demonstrated by the activation of caspase-3 and caspase-7 and the cleavage of poly (ADP-ribose) polymerase 1 (PARP1), and led to the suppression of the expression of proteins relevant to oncogenesis, proliferation and survival (for example, cyclin A, cyclin E, cyclin D3, CDC2, CDC6, and BCL-xL, MYC and ERG) (Fig. 1e,f and Supplementary Fig. 1d ). Consistently with the protein's crucial role in proliferation and survival, ectopic expression of ROR-γ in androgen-sensitive LNCaP cells promoted cell growth in androgen-deprived conditions (Supplementary Fig. 1e ).
ROR-g-selective antagonists inhibit CRPC growth and survival
Recent studies identified several ROR-γ-specific antagonists (for example, SR2211, GSK805 and XY011(also known as 8k); Fig. 2a ) [19] [20] [21] [22] [23] . SR2211 and GSK805 have been evaluated for their therapeutic potential in the suppression of T helper 17 (Th17) cell-mediated autoimmune diseases in animal models 22, 24 . By combining the structural features of SR2211 and GSK805 with structure-based optimization, we developed compound XY018, which inhibited ROR-γ constitutive activity in human embryonic kidney 293T cells with high potency (half-maximal effective concentration (EC 50 ), 190 nM) ( Fig. 2a and Supplementary Fig. 2a-d) . Molecular docking demonstrated that XY018 may bind to the ROR-γ hydrophobic LBD through several conserved hydrogen bonds and hydrophobic interactions. For example, the phenyl group in the middle of XY018 probably forms a π-π interaction with the side chain of Phe378 of the LBD, whereas the amide group can form a direct hydrogen bond with Phe377. The nitro group and hydroxyl group at each end may form hydrogen bonds with Glu379 and His479, respectively. Molecular-dynamics simulations demonstrated that the ROR-γ-XY018 complex is very stable with these interactions (Supplementary Fig. 2e,f) .
Given the crucial function of ROR-γ in prostate cancer cells in vitro, we examined whether its antagonists possess any growth-inhibitory effects. All of the ROR-γ antagonists that we tested inhibited PCa cell line growth with higher potency than did ENZ ( Fig. 2b and Supplementary Fig. 3a-c) . Consistently with data showing the different expression patterns of RORA and RORC, ROR-α-selective antagonist SR3335 (ref. 25) did not inhibit CRPC cell line growth. Moreover, strong growth inhibition by XY018 and SR2211 was observed in other AR-positive PCa cell models, including 22Rv1, VCaP, LNCaP, LAPC4 and PC346C (Supplementary Fig. 3a-c) . No significant growth inhibition by the ROR-γ antagonists was seen in the nonmalignant human prostate cell line RWPE1, in normal IMR90 human fibroblasts or in AR-negative PCa cells at the concentrations tested ( Supplementary  Fig. 3b,c) . Consistently with the induction of apoptosis by RORC gene knockdown, treatment of C4-2B and 22Rv1 cells with XY018 or with SR2211 reduced colony formation and increased apoptosis, as compared to treatment with vehicle ( Fig. 2c-e and Supplementary  Fig. 3d,e) . In line with the cellular effects, XY018 and SR2211 suppressed the expression of key proliferation and survival proteins, including that of MYC ( Fig. 2f and Supplementary Fig. 3f,g ). 
ROR-g antagonists inhibit AR signaling
We next analyzed RNA-seq transcriptomes of C4-2B cells treated with the two structurally distinct antagonists SR2211 and XY011 individually to identify gene programs that are affected by ROR-γ inhibition. Clustering of genes whose expression was significantly altered by either antagonist (relative to vehicle) revealed a high degree of concordance in the expression changes that were induced by each of the two ROR-γ inhibitors; the expression of more than 75% of genes was either decreased (cluster 1) or increased (cluster 3) by both antagonists (Fig. 3a) . Notably, genes of an AR activity signature, derived from androgen-sensitive PCa cells and human tumors, and which is of value in predicting clinical tumor response to androgen-ablation therapy 26 , constitute part of the two major clusters (cluster 1 and 3). Genes that are characterized as AR targets or androgen-induced genes were strongly inhibited by both antagonists; conversely, androgen-repressed genes were induced by the ROR-γ antagonists (Fig. 3a) . Genes linked to androgen-induced cancer cell proliferation and survival were also present in cluster 1 (for example, IGF1, RUNX2, UHRF1, MCM10, RRM2 and CCNE2) and in cluster 3 (for example, FAS, CDKN1B, DAB2IP and PTEN) (Supplementary Fig. 4a) . Moreover, the gene-expression profiles induced by the antagonists overlapped significantly with that of antiandrogen ENZ (41% overlap with SR2211; 38% overlap with XY011 for downregulated genes) ( Fig. 3a and Supplementary Fig. 4b ).
Further examination by gene-set enrichment analysis (GSEA) using the AR activity signature 26 revealed a robust disruption of AR target gene programs by ROR-γ antagonists (Fig. 3b) . The ROR-γ antagonists also inhibited the expression of genes that are preferentially upregulated by AR-V7 (ref. 27) , and the expression of most genes in the 16 AR-target gene set recently identified in human CRPC tumors 28 ( Supplementary Fig. 4c,d ). Fig. 3c and Supplementary Fig. 4e ).
Inhibition of ROR-g suppresses AR expression and genome binding
The prominent effect on AR-controlled gene programs of ROR-γ inhibition prompted us to investigate whether ROR-γ controls the expression and/or the function of AR. Indeed, ROR-γ knockdown suppressed the mRNA and the protein expression of full-length AR and of AR variants, including AR-V7, in C4-2B and VCaP cells. The ROR-γ antagonists (XY018, SR2211 and XY011) also inhibited the expression of AR and AR-V7 at both the mRNA and protein levels in a dose-dependent manner (Fig. 4a,b and Supplementary  Fig. 5a,b) . Similar dose-dependent inhibition was observed in other AR-positive cancer cell lines, including 22Rv1, LAPC4 and PC346C (Supplementary Fig. 5c ). Conversely, ROR-γ overexpression strongly increased AR expression in LNCaP cells (Supplementary Fig. 5d ). 
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Consistently with the results from cell models, the expression of RORC mRNA in multiple data sets from human CRPC tumors was correlated strongly not only with AR expression, but also with a CRPC AR activity signature 28 ( Supplementary Fig. 5e,f) .
To assess the effect of the ROR-γ antagonist on AR function, we performed anti-AR ChIP-seq by using C4-2B cells treated with 5 µM of SR2211 for 24 h; this caused an incomplete suppression of AR expression (Supplementary Fig. 6a ). Treatment with SR2211 reduced genome-wide AR binding to its target loci, as well as genome-wide abundance of histone 3 lysine 27 acetylation (H3K27ac), as compared to treatment with vehicle ( Fig. 4c and Supplementary Fig. 6b) . AR binding at enhancers and/or promoters of targets such as KLK2, KLK3, CAMKK2, NKX3-1, FKBP5 and ATAD2 was almost completely eliminated by SR2211 ( Fig. 4c, right; and Supplementary Fig. 6c ). Similar inhibition of AR binding was seen by antagonist XY018 in ChIP-qPCR analysis (Fig. 4d) . In line with the loss of AR occupancy, transcriptional activation-linked histone marks, including H3K27ac, H3K4me2 and H3K4me3, were significantly (P < 0.01) reduced by SR2211 at the KLK3 promoter and enhancer, as compared to vehicle. As expected, RNA polymerase II (Pol II) recruitment at the target promoters was also reduced by SR2211, as compared to vehicle ( Fig. 4e and Supplementary Fig. 6d,e) . Consistently with the effects of SR2211, knockdown of RORC showed similar inhibitory effects on AR binding and on associated histone marks (Supplementary Fig. 6f ). The overall genome-wide distributions of H3K4me2 and H3K4me3 marks, as well as of Pol-II peaks, were not markedly affected by SR2211 (Supplementary Fig. 6g ), which indicates that ROR-γ inhibition of H3K4me2, H3K4me3 and Pol-II is target locus-specific.
The ROR-γ-selective antagonists SR2211, XY018 and XY011 were identified on the basis of the unique pocket structure of the ROR-γ LBD. Nevertheless, to rule out the possibility that the antagonists act directly through AR, we performed a reporter-gene assay. In a multimerized androgen response element (ARE)-driven reporter that can be activated by synthetic androgen R1881 and repressed by antiandrogen ENZ, the three ROR-γ antagonists (in concentrations up to 10 µM) did not influence R1881-induced AR activity ( Supplementary  Fig. 7a) . Moreover, molecular docking demonstrated that although XY018 could dock snugly into the ROR-γ ligand-binding pocket, it simply cannot be accommodated by the AR ligand-binding pocket, because of the pocket's short length (Supplementary Fig. 7b ).
To provide further evidence that the ROR-γ antagonists act through the suppression of AR expression, we performed AR-rescue experiments. First, we ectopically expressed an LBD-truncated form of AR in LNCaP cells, and we found that growth inhibition by the antagonists was effectively mitigated in the cells, whereas endogenous AR expression was suppressed (Supplementary Fig. 7c ). Next, we performed a reporter assay with a 5.8 kb KLK3 regulatory sequence-linked luciferase gene. Both the androgen-independent and the androgenstimulated activities of endogenous AR were strongly inhibited by the ROR-γ antagonists, probably because of the suppression of AR expression ( Supplementary Fig. 7d ). However, AR ectopic expression effectively blocked inhibition by the antagonists. By contrast, the anti-androgen ENZ was still effective in blocking the activity of ectopic AR. Taken together, our results strongly suggest that the ROR-γ antagonists, acting through ROR-γ, effectively suppress aberrant AR expression and function.
ROR-g directly controls AR gene expression
The potent inhibition of AR expression by RORC knockdown or by ROR-γ antagonists led us to examine whether ROR-γ directly controls AR gene transcription. ROR-γ binds DNA with the specific sequence motifs A(A/T)NTAGGTCA (the classic RORE motif) or C(T/A)(G/A) GGNCA (the variant RORE motif) 13, 31 . In C4-2B cells, ChIP-qPCR of regions containing more than 20 putative ROREs across the 250-kb 
Fold change (log 2 ) npg AR locus demonstrated that ROR-γ bound to a site in the first exon (2.3 kb downstream of the AR transcription start site (TSS)) (Fig. 5a) . The site contains sequences that match the variant RORE motif. When cells were treated with SR2211, ROR-γ binding was reduced, as compared to treatment with vehicle ( Fig. 5a) .
To examine the function of the putative RORE-containing site in mediating ROR-γ regulation of the AR gene, we used a lentiviral CRISPR-Cas9 editing system to initially delete the site with two sets of small guide RNAs (sgRNAs) in C4-2B cells (Fig. 5b,c and Supplementary Fig. 8a ). Because cell proliferation and survival is dependent on highly elevated AR expression, which thus prevented us from expanding cell clones with genome editing-reduced AR, we analyzed heterogeneous populations of cells, some of which were edited, and some of which were probably not. We found that even deletion in about half of the cell population (estimated from the PCR products of the wild-type (WT) and deleted alleles; Fig. 5c , left) resulted in a significant reduction in the abundance of AR transcripts, as compared to control sgGFP-treated cells, which were detected by the upstream primers P1 and P2 (Fig. 5d) . Next, we treated the editing-heterogeneous cell populations with the ROR-γ antagonists and analyzed AR transcripts with primers P3 and P4. As expected, the three antagonists reduced the abundance of transcripts from the WT allele, as compared to treatment with vehicle. By contrast, in the same samples, transcript levels from the deleted alleles were not significantly altered by any of the antagonists (Fig. 5e and Supplementary Fig. 8b ), which indicates that the site is required for ROR-γ antagonist-mediated inhibition of AR transcription. Moreover, as expected from the frameshifting effects caused by indels, the three sgRNAs, when used individually, caused a 'knockout' effect on AR protein expression (Supplementary Fig. 8c ). Importantly, sgRNA-2, the only one that could be designed to cause indel-type alterations adjacent to the RORE sequence, also significantly (P < 0.01) inhibited AR mRNA expression, whereas the other two sgRNAs did not (Supplementary Fig. 8c ). Finally, we performed reporter-gene assays npg on the RORE, and we found that it was highly responsive to ROR-γ-mediated transactivation. Mutations in the core RORE sequence, or deletion of the ROR-γ C-terminal, activation function 2 (AF2), completely abrogated the AR-RORE-dependent activation. The three ROR-γ antagonists suppressed this activation in a dose-dependent manner (Fig. 5f) npg the inhibition of ROR-γ activity (in 293T cells), the inhibition of AR expression (in C4-2B) and the inhibition of cell proliferation (in C4-2B) (Supplementary Fig. 8d,e) . ROR-γ activates gene transcription through association with co-factors such as nuclear receptor coactivator (NCOA, also known as steroid receptor coactivator (SRC)) family members 32 . Indeed, NCOA1 (also known as SRC-1) and NCOA3 (also known as SRC-3) occupied the AR-RORE site. Furthermore, their binding was strongly reduced by ROR-γ antagonists or by RORC knockdown, as compared to treatment with vehicle or control siRNA, respectively ( Fig. 5g and Supplementary Fig. 8f) , indicating that the SRCs were recruited to the site via ROR-γ. Knockdown of SRC-1 and SRC-3, but not of SRC-2 (also known as NCOA2), individually or in combination, decreased AR mRNA and AR protein expression. Treating cells with bufalin, a cardiac glycoside inhibitor that was recently shown to selectively degrade SRC-1 and SRC-3 in cancer cells 33 , also resulted in dose-dependent inhibition of AR mRNA and AR protein expression (Supplementary Fig. 8g,h) . Next, we assessed the effect of ROR-γ inhibition on the local chromatin. Treatment with SR2211 significantly reduced the abundance of the gene-activating marks H3K4me3 and H3K27ac at the RORE site and AR promoter ( Fig. 5g and Supplementary Fig. 8i) , as compared to treatment with vehicle.
Consistently with the reduction of AR transcripts, Pol II occupancy at the AR promoter and the RORE site was significantly (P < 0.01) inhibited by ROR-γ inhibition.
ROR-g antagonists inhibit CRPC tumor growth
We next evaluated the effects of ROR-γ antagonists on prostate cancer tumor growth. Given the heterogeneity of PCa, we generated xenografts using PCa cell lines with distinct features (for example, C4-2B cells that express AR with mutant LBDs; VCaP cells with amplified AR gene and AR-V7 expression; 22Rv1 cells that express high levels of multiple AR variants; and AR-negative PC3 cells). In mice bearing the three AR-positive tumor models-including ENZ-resistant 22Rv1-a 5 mg/kg intraperitoneal injection of SR2211 (five times per week when tumors reached approximately 100 mm 3 ) stopped tumor growth (Fig. 6a,b and Supplementary Fig. 9a ). Tumor growth inhibition was also observed when the other antagonists, XY018 and XY011, were used, as well as after shRNA knockdown of RORC in these models (Supplementary Fig. 9b-e) . Moreover, in an orthotopic model of PCa, treatment with SR2211 suppressed tumor growth ( Supplementary  Fig. 9f-h ). In line with a lack of any significant effect on the growth of PC3 cells in vitro (Fig. 2c) , SR2211 did not suppress the growth of PC3-derived xenograft tumors (Supplementary Fig. 9i ). npg Notably, the expression of AR and of AR target genes were markedly inhibited by SR2211, whereas tumor cell apoptosis, as measured by cleaved caspase-3 and caspase-7, was strongly induced by this antagonist (Fig. 6c) . ChIP-qPCR analysis of xenograft tumors showed that SR2211 treatment blocked ROR-γ binding to the AR-RORE site, and also blocked the binding of AR to KLK3, and the enrichment of H3K27ac (Supplementary Fig. 10) . Moreover, in a VCaP-derived mouse model of castration-resistant PCa, administration of the antagonist SR2211 alone (5 mg/kg) significantly inhibited CRPC tumor growth, whereas ENZ alone (10 mg/kg) did not. Co-administration of the two drugs resulted in the persistent suppression of tumor growth, which indicates that the ROR-γ antagonist can sensitize CRPC tumors to ENZ (Fig. 6d) . As previously reported 34, 35 , VCaP xenograft tumors result in micrometastasis in mice. SR2211 treatment inhibited metastasis to the femur and liver (Fig. 6e) .
Similarly to ENZ, the ROR-γ antagonists were well tolerated by the treated mice, given the lack of change in their body weight or in the weight of their vital organs, and in their behaviors, such as food and water consumption, grooming and alertness (Supplementary Figs. 9a-d ,j and 11a; data not shown). Consistently with the role of ROR-γ as an adipogenesis factor 36 , its antagonist reduced the amount of white adipose tissue. Thus, the antagonists can block CRPC tumor growth and effectively sensitize tumors to ENZ, without causing overt toxicity. Notably, unlike ENZ, the antagonists did not display any discernible effect on the growth of androgen-responsive tissues, such as mouse prostate and testis, or on AR expression in the tissue ( Supplementary  Fig. 11b-d) . Analysis of two nonmalignant human prostate epithelial cells showed that the antagonists did not have any significant effect on endogenous AR expression (Supplementary Fig. 12a ). To explore the underlying mechanism, we performed ChIP-qPCR and found no detectable ROR-γ binding to the RORE-corresponding site in mouse prostate tissue or in the two human cell lines (data not shown). Immunoblotting revealed very low levels of ROR-γ expression in the human cells (Supplementary Fig. 12a ). Sequence comparisons showed that the corresponding site on the mouse Ar gene lacks a functional RORE (refs. 13,14) (Supplementary Fig. 12b ). Taken together, our results suggest that the ROR-γ antagonists can inhibit AR expression specifically in tumor cells and not in nonmalignant cells.
DISCUSSION
The most common mechanism driving CRPC development seems to be reactivated AR signaling mediated by high levels of AR and its variants in PCa. There are a lack of therapeutically actionable means to effectively suppress AR expression. Our study demonstrates not only that ROR-γ acts as a key determinant of AR gene expression, but also that it provides a unique opportunity to explore an effective therapeutic intervention for CRPC. We found that ROR-γ directly stimulates AR gene transcription by binding to an exonic RORE, and partly through the NR coactivators SRC-1 and -3. Although SRCs and other AR coactivators probably have important roles in prostate cancer 37-41 , they have not been shown to be directly involved in AR gene overexpression. We demonstrate here that small-molecule antagonists of ROR-γ potently disrupt the binding of ROR-γ and the SRCs to the AR locus; reduce the local activating histone marks; and effectively suppress AR expression in vitro and in vivo. Transcription factors such as E2F1, LEF, TCF and nuclear factor (NF)-κB can activate AR expression, whereas others have been shown to suppress it [42] [43] [44] [45] [46] . It is possible that ROR-γ also acts in concert with them or other factors.
The alternatively spliced variants of AR in tumors treated by antiandrogens and cytochrome P450 family 17 subfamily A member 1 (CYP17A1) inhibitors (for example, ENZ and ABI) are linked to therapeutic resistance and metastasis 47 . Recently, agents that target the AR N-terminal domain (NTD), an intrinsically unstructured domain, or that enhance degradation of the full-length AR protein, are in development [5] [6] [7] [8] . We propose that targeting ROR-γ with its selective antagonists effectively inhibits the expression of AR variants, such as AR-V7, as well as full-length, at the gene-transcriptional level, thereby mitigating or even eliminating the root cause of the problem-namely, the highly elevated AR gene transcripts and proteins. The ROR-γ antagonists potently inhibited the growth of different AR-positive xenograft tumors in mice, including those with AR gene amplification and/or high levels of AR variants. Notably, tumors that are resistant to ENZ are sensitive to the antagonists (either alone or in combination with ENZ), which suggests that ROR-γ targeting can have broad clinical utility in PCa. The effect of the ROR-γ antagonists on AR expression, instead of on AR LBD function, may also offer other therapeutic advantages over anti-androgens. Indeed, unlike anti-androgens that suppress the growth and function of normal androgen-responsive tissues, such as testis and prostate, the ROR-γ antagonists do not show any significant effect on the size of the mouse tissues or on AR expression in the tissues, or in human nonmalignant prostate cells, because of the lack of ROR-γ function. This tumor-specific effect of the antagonists is probably attributable to the addiction of tumor cells to elevated levels of AR, and to tumor cell-specific control of AR by ROR-γ.
The effect of ROR-γ antagonists on AR-regulated gene programs in CRPC cells seems to be extensive, encompassing AR targets that are upregulated, downregulated or persistently expressed in CRPC tumors 28 . However, the overall impact on CRPC tumors is unlikely to be limited to AR and its programs. An inflammatory tumor microenvironment is thought to promote CRPC and tumor metastasis through the production of cytokines such as IL- 17 (refs. 48,49) . Thus, ROR-γ in tumor-inflitrating lymphocytes could play an important part. Therefore, the targeting of ROR-γ can stop tumor growth and metastasis, possibly through blocking multiple pathways-including aberrant AR signaling. As more potent and orally bioavailable ROR-γ antagonists are being developed and entering clinical trials to treat human autoimmune diseases, our findings here may have immediate implications on the development of a new generation of prostate cancer therapeutics.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cell culture. LNCaP, C4-2B, 22Rv1, PC-3 and PC346C prostate cancer cells were cultured in RPMI1640; VCaP, HEK293T and human fibroblast IMR90 cells were in Dulbecco's Modified Eagle's Medium (DMEM); LAPC-4 was in Iscove's MEM (all from Corning); and RWPE-1and PZ-HPV-7 were in Keratinocyte Serum Free Medium (K-SFM) (Invitrogen) with the supplements. All culture media except for RWPE-1 and PZ-HPV-7 were supplemented with 10% FBS (Hyclone or Gemini), except where indicated otherwise. For experiments, C4-2B cells were cultured in RPMI supplemented with 9% cds-FBS, plus 1% regular FBS (to mimic the CRPC condition), unless indicated otherwise. 22Rv1 cells were cultured in RPMI supplemented with 10% cds-FBS. LN/TC-AR cells that inducibly express a C-terminally truncated variant of AR were derived from LNCaP cells, as previously described 50 . Cells were grown at 37 °C in 5% CO 2 incubators. LNCaP, VCaP, 22Rv1, PC-3, 293T, IMR90, PZ-HPV-7 and RWPE-1 were from American Type Culture Collection (ATCC). C4-2B was from UroCor Inc. (Oklahoma City, OK). The prostate cancer cell lines were recently authenticated by ATCC using short tandem repeat (STR) profiling. Cell lines were regularly tested to ensure negativity for mycoplasma.
Chemicals. Sources for chemicals are as follows: SR2211, Calbiochem and TOCRIS; SR1555 and SR3335, Cayman. Information on XY018 and XY011 is provided below or described before 21 . Other chemicals are from Sigma-Aldrich, unless indicated otherwise.
qRT-PCR and immunoblotting analysis. Total RNA was isolated from cells in six-well or 10-cm plates or from xenograft tumors, and cDNA was prepared, amplified and measured in the presence of SYBR, as previously described 51 . Briefly, the fluorescence values were collected, and a melting-curve analysis was performed. Fold difference was calculated as described previously 51 . The experiments were performed at least three times, with data presented as mean values ± s.d. Cell lysates were analyzed by immunoblotting with antibodies specifically recognizing ROR-γ, AR, AR-V7 and the indicated proteins. The PCR primers and all the antibodies used in this study are described in the Supplementary Tables 1 and 2 .
Analysis of RORs mRNA expression, genetic alterations and association with CRPC AR signature in clinical tumors. Publicly available PCa expression data sets GSE6919, GSE35988, GSE6811 and GSE70768 from previous studies [52] [53] [54] [55] were downloaded from the GEO at http://www.ncbi.nlm.nih.gov/geo/. The data sets contain gene-expression profiles of benign, primary, metastatic and/or CRPC tumor samples. Normalized probe set expression for RORs were compared between the different tissue and tumor groups by a two-tailed t test for significance. Computations were conducted in R statistical package (https:// www.r-project.org/). For genetic alterations of ROR genes, data from a recent genomics study 18 at the cBioPortal for Cancer Genomics (http://www.cbioportal. org) was interrogated, and OncoPrint displays of gene alterations were presented. Expression correlation between ROR-γ and AR in tumors was assessed by computing the Pearson correlation coefficient (r) and a two-tailed t test for significance. For correlation between RORC expression and the AR signature activity, the expression of the 150 CRPC AR-signature genes 28 is summarized as a single expression profile, as previous reportedly 56 , before application to computation of the Pearson correlation statistics.
Immunohistochemistry (IHC) and statistics analysis. IHC was performed as previously described 51, 57 , with the following modifications. Antigen retrieval for sections of tissue microarrays (TMA PR803b, US Biomax, Inc.) was performed in a pressure cooker. The slides were then incubated with anti-ROR-γ monoclonal antibody (AFKJS-9, eBioscience) at 1:50 dilutions overnight at 4 °C, followed by incubations with biotinylated secondary antibody and the ABC reagents in the Vectastain Elite kit, and then counterstained with hematoxylin. The tissue microarray (TMA) contained specimens from 70 cases of prostate cancer, with information provided for most of the cases on stage, Gleason scores and TNM grading. The percentage of positive nuclear staining was scored as follows: 0-<5%, score 0; 5-<10%, score 1; 10-50%, score 2; >50%, score 3. Differences and correlations in immunostaining among groups were analyzed with the χ 2 test.
Cell viability, apoptosis and growth assays, and colony formation. For cell viability, cells were seeded in 96-well plates at 1,500-2,500 cells per well (optimum density for growth) in a total volume of 100 µl of media. Serially diluted compounds in 100 µl of media were added to the cells 12 h later. After 4 d of incubation, Cell-Titer GLO reagents (Promega) were added, and luminescence was measured on GLOMAX microplate luminometer (Promega), according to the manufacturer's instructions. All experimental points were set up as sextuplicates as biological replication, and the entire experiment was repeated three times. The data are presented as a percentage of viable cells, with vehicle-treated cells set at 100. The estimated in vitro half-maximal inhibitory concentration (IC 50 ) values were calculated using GraphPad Prism 6 software (GraphPad).
For apoptosis, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was performed by using in situ cell death detection kit (Roche), as previously described 57 . The results are expressed as a percentage of apoptotic cell number/total cell number. Caspase-3/7 activity was measured by using a luminescent caspase-Glo 3/7 assay kit (Promega Corporation, Madison, USA), following the manufacturer's instructions. For cell growth, cells were seeded in 6-well plates at 2 × 10 5 per well and treated as indicated. Total viable cell numbers were counted with a Coulter cell counter. For colony formation, 800 cells were seeded in a well of 6-well plates and cultured for 14 d, with the medium changed every 3 d. When the cell clone grew visible, the medium was removed, and the cells were fixed with 10% formalin for 10 min. Then, the plates were washed with PBS two times, and the cell colonies were stained with 0.2% crystal violet (in 10% formalin) for 15 min. The numbers of cell colonies were counted after being washed five times with PBS. The above assays were performed in triplicates, and the entire experiments were repeated three times.
ROR-g shRNA and overexpression lentivirus production and siRNA transfection. Lentiviral plasmids encoding shRNA targeting ROR-γ/RORC (TRCN0000033655 and TRCN0000033658) were purchased from SigmaAldrich. Nontargeting control shRNA were used as described 51 . For ROR-γ overexpression, human ROR-γ cDNA in pLX304 (DNASU) was amplified, and cloned into a modified pLX304 vector with a V5 tag at the receptor N terminus. Lentiviral particles were produced in 293T cells after co-transfection of the above lentivirus vectors, psPAX2 and pMD2.G in 10-cm dishes, as described 51 . siRNAs for gene knockdown were purchased from Dharmacon. The siRNA target sequences for ROR-γ and different SRCs are listed in Supplementary Table 3 . Transfections were performed with OptiMEM (Invitrogen) and Dharmafectin 1 (Dharmacon), following the manufacturer's instructions.
Reporter constructs and reporter-gene assays. Transient transfection and reporter-gene assays were performed as previously described 51 , with following modifications. ARE reporter-gene assays were performed by transfecting 22Rv1 cells with 5 × ARE-tk-luc, pcDNA3.1-hAR and pCMV-β-gal for normalization. For transfection with constructs omitted for specific gene expression, corresponding empty vectors were used to ensure that equal amounts of total DNA were used. Briefly, 22Rv1 cells seeded in 96-well plates in hormone-deprived medium supplemented with 10% cds-FBS (Hyclone) were transfected with lipofectamine 2000 (Life technology, Carlsbad, CA, USA) and the indicated plasmid DNA. Cells were then treated at 12 h after transfection with 3-nm R1881 and the indicated concentrations of ROR-γ antagonists or ENZ for another 24 h, before being harvested for β-gal and luciferase assays. For RORE reporter-gene assays, 4 × AR-RORE-tk-luc was constructed by inserting four copies of the newly identified AR-RORE TTCTGGGTCA into the tk-luciferase reporter vector. The AR-RORE mutant form (AR-RORE mut) contains sequences mutated from TTCTGGGTCA to TTCTGAACGA. Cells (HEK293T) were co-transfected with CMX-ROR-γ or with CMX-ROR-γ∆H12 expression vectors and the RORE-tk-luc reporter plasmid as indicated, using Lipofectamine 2000 (Life Technology, Carlsbad, CA, USA). After 12 h of incubation, cells were treated with vehicle or ROR-γ antagonists as indicated, for another 24 h. For Gal4-driven reporter assays, 293T cells were transfected with Gal4-ROR-γ LBD and pGL5-luc reporter. The luciferase and β-galactosidase were then analyzed with a Luciferase Assay Substrate (Promega) and Luminescent β-galactosidase Detection Kit II (Clontech). All transfections were performed in triplicate, and each experiment was repeated at least three times. npg Molecular docking and molecular dynamics simulation. Schrödinger 2014 Suite was used to predict the potential binding mode of ROR-γ and its ligands. The crystal structure of the ROR-γ LBD in complex with the antagonist (PDB code: 4QM0.pdb) was used as the reference structure in the docking study. Protein-structure preparation for docking studies included water deletion, hydrogen-atom addition and protonation-state adjustment. All ligand and protein preparations were performed in Maestro (version 9.9, Schrödinger, LLC, New York, NY, 2014) implemented in the Schrödinger program (http://www. schrodinger.com). In this study, ligands were prepared by using the Ligprep module to obtain energy-minimized 3D structures, which were then docked into the ligand-binding pocket with the Glide molecular-docking program (version 6.4, Schrödinger, LLC, New York, NY, 2014) using the Glide SP and Glide XP modes. For all methods, Glide docks flexible ligands into a rigid receptor structure. Final ranking from the docking was based on the docking score, which combines the Epik state penalty with the Glide Score. Finally, the binding poses with the top glide score (20 poses) were clustered and selected for further visual evaluation and molecular-dynamics simulations.
Molecular-dynamics simulations were conducted by using the AMBER 14 program (University of California, San Francisco). The starting coordinates were obtained from docking results. For ligand coordinates, the representative poses of each cluster were chosen. For protein coordinates, the protein preparation panel in the Schrodinger 2014 Suite was applied to assign the protonation states and orientations of residues, which were then further processed by using LEaP module in the AMBER 14. Parameters of the compounds were prepared with an AM1-bcc model, and the other parameters were assigned from the AMBER GAFF force field using ANTECHAMBER. Topology and parameter files for the protein, ligand and complex were generated using the LEaP module in the AMBER 14. TIP3PBOX water molecules were added in cube periodic boxes, which were 10 Å × 10 Å × 10 Å. To ensure the overall charge neutrality of the system, appropriate Na + and Cl − were added to the box. For each system, energy minimization and molecular-dynamics simulations were carried out using the GPU version of the Particle Mesh Ewald molecular dynamics (PMEMD) program in the AMBER14. The molecular-dynamics simulations were performed for up to 200 ns for each complex system. The coordinates of the complexes were saved every 2 ps, and those snapshots were taken in production runs for detailed analysis. Trajectories were analyzed using the PTRAJ module in AMBER14.
Alphascreen assay. The human ROR-γ LBD (residues 262-507) was expressed as a His6-fusion protein using the pET24a expression vector (Novagen, Madison, WI), as described in reference 11 . Interactions between ROR-γ and ligands were assessed by luminescence-based AlphaScreen technology (Perkin Elmer) using a histidine detection kit from PerkinElmer (Norwalk, CT). All of the reactions contained 100 nM receptor LBD bound to nickel acceptor beads (5 µg/ml) and 20 nM biotinylated SRC1-4 peptide bound to streptavidin donor beads (5 µg/ml) in the presence or absence of the indicated amounts of control compounds SR2211 or candidate compounds. The N-terminal biotinylated coactivator peptide SRC1-4 sequence was QKPTSGPQTPQAQQKSLLQQLLTE. Compound concentrations varied from 150 nM to 200 µM in the dose-response assay.
Thermal-shift assay. All reactions were carried out using a CFX96 real-time PCR system (Bio-Rad). Protein were buffered in 10 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.5, 150 mM of NaCl and 5% glycerol at a concentration of 7.5 µM. Compounds were added at a final concentration of 200 µM. All assays were set up in a 20-µL final-reaction volume in a 96-well plate with 10 × SYPRO Orange (Invitrogen), and were incubated with compounds on ice for 30 min. The samples were heated from 30 °C to 90 °C with a thermalramping rate of 1 °C per min, and the fluorescence signals were read out. ∆Tm was recorded as the difference between the transition midpoints of sample and reference wells containing the protein without ligand in the same plate. N-(2′-fluoro-4′-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-[1,1′-biphenyl]-4-yl)-2-(2-nitrophenyl) acetamide (XY018). Reagents and solvents were obtained from commercial suppliers and used without further purification. Flash chromatography was performed using silica gel (300-400 mesh). All reactions were monitored by TLC, using silica-gel plates with fluorescence F254 and UV light visualization. 1 H-NMR (nuclear magnetic resonance) spectra were recorded on a Bruker AV-400 spectrometer at 400 MHz. Coupling constants (J) are expressed in hertz (Hz). Chemical shifts (δ) of NMR are reported in parts per million (p.p.m.) units relative to internal control (TMS). The low-or high-resolution of electrospray ionization mass spectrometry (ESI-MS) was recorded on an Agilent 1200 HPLC-MSD mass spectrometer or Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer, respectively.
Synthesis of
To 2-fluoroaniline (6 g, 54 mmol) in a pressure vessel was added hexafluoroacetone trihydrate (12.5 g, 56.7 mmol) and p-toluenelsuphonic acid (0.85 g, 5.4 mmol). The reaction mixture was stirred at 90 °C for 12 h. After water was added, it was extracted with ethyl acetate, and the organic layer was washed with saturated NaHCO 3 solution and brine and dried over Na 2 SO 4 . The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica-gel chromatography with petroleum ether/ethyl acetate (10/1, v/v) to yield 2- (4-amino-3-fluorophenyl)-1,1,1,3,3 To a solution of 1,1,1,3,3,3-hexafluoro-2-(3-fluoro-4-iodophenyl) propan-2-ol (6.2 g, 16 mmol) in 1,4-dioxane (100 ml) and water (20 ml) was added (4-((tert-butoxycarbonyl)amino)phenyl)boronic acid (4.2 g, 17.6 mmol), followed by the addition of potassium carbonate (6.6 g, 48 mmol) and Pd(PPh 3 ) 4 (0.9 g, 0.78 mmol). The vessel was purged with argon, sealed and heated to 80 °C for 5 h. Water was added to the residue, and the mixture was extracted with ethyl acetate, the organic layer was washed with brine and dried over Na 2 SO 4 . The solid was filtered off, and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica-gel chromatography with petroleum ether/ethyl acetate (20/1, v/v) to yield tert-butyl(2′-fluoro-4′- (1,1,1,3 To a solution of 2-(2-nitrophenyl) acetic acid (56 mg, 0.31 mmol) in DCM (20 ml) was added HATU (213 mg, 0.56 mmol) and DIPEA (0.5 ml). The mixture was stirred at room temperature for 5 min, before 2-(4′-amino-2-fluoro-[1,1′-biphenyl]-4-yl)-1,1,1,3,3,3-hexafluoro propan-2-ol (100 mg, 0.28 mmol) was added. The reaction mixture was stirred at room temperature for 3 h. Water was added to the mixture, which was extracted with ethyl acetate. The organic layer was washed with brine and dried over Na 2 SO 4 . The solid was filtered off and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by silica gel chromatography with petroleum ether/ethyl acetate (4/1, v/v) to yield N- (2′-fluoro-4′-(1,1,1,3,3 
